Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer (Mimosa trial) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 05, 2011

Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer (Mimosa trial)





 WHAT IS THE MIMOSA TRIAL?
MIMOSA is a demanding multinational trial started in December 2006 with a 9 years of duration. About 900 patients with advanced ovarian cancer who have had an optimal response to the initial treatment (surgery + chemotherapy) have been included in the study with the aim to test the efficacy and safety of the vaccination with Abagovomab for the prevention or the delay of disease’s recurrences. The first results will be available at the end of 2010.


0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.